Received FDA clearance of Investigational New Drug application (IND) for PRT12396, mutant-selective JAK2V617F inhibitor in ...

Manage your stage 3 ET diagnosis with this guide on high-risk treatments, side effects and new NCCN-preferred options to empower your next visit. While essential thrombocythemia (ET) is classified as ...

Series B funds will enable clinical development of ATV-1601, an oral allosteric AKT1-selective inhibitor for the treatment of Hereditary ...

NEW YORK – Cogent Biosciences expects the US Food and Drug Administration to decide whether to approve its KIT D816V tyrosine kinase inhibitor bezuclastinib as a treatment for non-advanced systemic ...

The MarketWatch News Department was not involved in the creation of this content. DOVER, Del., Dec. 17, 2025 /PRNewswire/ -- Eilean Therapeutics announced the advancement of ZE74-0282 into ...

CAMBRIDGE, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Atavistik Bio, a biotechnology company discovering the next generation of precision allosteric therapeutics, today announced that it will unveil the ...

Background: Left ventricular thrombus (LVT) is often associated with anterior myocardial infarction (MI) and reduced ejection fraction (EF). However, it could be present in patients with no prior ...

Case: A 60-year-old man with history of hypertension, diabetes, and remote history of unprovoked lower extremity DVT presented with dyspnea for 3 days and chest pain for 1 day. Initial ECG revealed ...

ZRSR2 mutations are linked to JAK2 V617R-driven MPNs but are insufficient alone for disease progression. CRISPR-Cas9 studies showed ZRSR2 loss causes intron retention and transcriptional changes ...

A study published in the Proceedings of the National Academy of Sciences by scientists from Israel and Ghana shows that an evolutionarily significant mutation in the human APOL1 gene arises not ...

VGT-1849B, a selective JAK2 inhibitor, targets JAK2 mRNA to reduce protein production, potentially improving safety profiles over existing therapies. Polycythemia vera is a rare myeloproliferative ...